Current Illinois CancerCare Clinical Trials

Study of Subcutaneous Epcoritamab in Combination with Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants with Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Study Number: M22-003

Study Summary:
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with previously untreated FL. Adverse events and change in disease condition will be assessed.

Status: Open

Study Coordinator(s)
  • Navigator Heather, 309-243-3661 hthulean@illinoiscancercare.com
  • Hannah, 309-243-3628 hknight@illinoiscancercare.com

Study Link

« Search Again